Clinical Trials Browser

UNKNOWN × tislelizumab × Thoracic × Clear all

NCT04620837 2020-11-09

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Phase 2 Unknown

Small Cell Lung Carcinoma